Jyoti Bhat, MD
Endocrinology · Concord
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 11
- Since medical school
- 18 years
- Icahn School of Medicine at Mount Sinai, 2008
Offices
11 locations · Jiva Health Inc · 46 clinicians in this group
Hospitals listed: Contra Costa Regional Medical Center · John Muir Medical Center - Concord Campus · John Muir Medical Center - Walnut Creek Campus · Stanford Health Care Tri-Valley. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Bhat’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence A110293 · Current
Licensed to practise in California · since 2009 · expires 2027-08-31 · Mount Sinai School of Medicine of New York University.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
4 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Contra Costa Regional Medical CenterMartinez, CAAcute Care Hospital · Government - Local · Has an emergency department · Birthing-friendlyPart of Contra Costa Health ServicesPatients rate it 3 of 5 · 73% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.167, Oct 2024 – Sep 2025
- John Muir Medical Center - Concord CampusConcord, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 4 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.235, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.675, Oct 2024 – Sep 2025
- John Muir Medical Center - Walnut Creek CampusWalnut Creek, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of John Muir Health, which runs 3 hospitalsPatients rate it 3 of 5 · 77% would definitely recommend itOverall rating: 2 of 5 starsWorse than the national rate — Abdominopelvic accidental puncture or laceration rate: 2.01 (1.17 to 2.85) · 2,206 cases, Jul 2022 – Jun 2024Worse than the national rate — Death rate among surgical inpatients with serious treatable complications: 222.42 (177.82 to 267.02) · 120 cases, Jul 2022 – Jun 2024Worse than the national rate — Pressure ulcer rate: 1.4 (0.91 to 1.9) · 9,764 cases, Jul 2022 – Jun 2024Worse than the national rate — SSI - Colon Surgery: 2.734, Oct 2024 – Sep 2025Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.536, Oct 2024 – Sep 2025Better than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.341, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.455, Oct 2024 – Sep 2025Better than the national rate — MRSA Bacteremia: 0.245, Oct 2024 – Sep 2025
- Stanford Health Care Tri-ValleyPleasanton, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Stanford Health Care, which runs 3 hospitalsPatients rate it 3 of 5 · 74% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0.178, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.237, Oct 2024 – Sep 2025
See every measure and the patient survey for Contra Costa Regional Medical Center
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 1 better, 4 the same, 0 worse of 5 measures. Readmissions: 1 better, 4 the same, 1 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.167 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.99 (0 to 2.04) · 188 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.08 (0.63 to 1.53) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 7.2 · 44 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8.8 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.4 · 114 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 12.3 · 27 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.7 · 321 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.44) · 1,181 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.26 (0.05 to 0.47) · 1,198 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.2 (0.67 to 5.72) · 216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 71 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.5 (0.82 to 4.18) · 195 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.36 (1.01 to 19.71) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.08) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 2.07 (0.55 to 3.58) · 67 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.93 (0 to 2.03) · 981 cases | No different | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.948 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 2.027 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21.3 · 101 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 52.2 · 126 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -53.6 · 112 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 87 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.7 (3.7 to 8.6) · 95 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.6 (8.8 to 17.8) · 95 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.2 · 35 cases | None | Jul 2023 – Jun 2025 |
What patients said (521 patients answered, 10% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 3 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 79% |
| Nurses "always" communicated well | 76% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 66% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 75% |
| Staff "always" explained new medications | 78% |
| Nurses "always" explained things so they could understand | 72% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 45% |
| "YES", patients would definitely recommend the hospital | 73% |
| Staff "always" explained possible side effects | 54% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for John Muir Medical Center - Concord Campus
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 0 better, 7 the same, 0 worse of 7 measures. Readmissions: 1 better, 9 the same, 1 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.235 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.675 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.11 (0.21 to 2) · 1,612 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.02 (0.77 to 1.28) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 184.13 (136.65 to 231.6) · 86 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.2 · 175 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.6 · 124 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10.4 · 172 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 8 · 537 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 13.5 · 434 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 13 · 215 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 3,208 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.32 (0.13 to 0.51) · 7,626 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.04 to 0.41) · 8,660 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.1 (1.29 to 4.91) · 2,723 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.21 (0 to 2.51) · 1,208 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 3 (1.7 to 4.3) · 2,355 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.77 (3.24 to 12.3) · 1,216 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 3.43 (0.43 to 6.43) · 1,253 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.93 (0.47 to 3.4) · 388 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.14 (0.58 to 1.69) · 6,288 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 263 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.636 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.254 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.904 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.5 · 312 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.1 · 768 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -6.8 · 295 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -3.1 · 648 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 31.1 · 433 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.1 · 504 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.7 (5.1 to 8.8) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 12.9 (10.5 to 15.7) · 476 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.1 · 250 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 8.8 · 154 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.7 · 186 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.4 (9.9 to 17.9) · 192 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.2) · 546 cases | No different | Jan 2024 – Dec 2024 |
What patients said (521 patients answered, 23% of those asked)
| Cleanliness | 4 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 72% |
| Nurses "always" communicated well | 78% |
| Doctors "always" communicated well | 80% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 86% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 79% |
| Doctors "always" treated them with courtesy and respect | 84% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 46% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 84% |
See every measure and the patient survey for John Muir Medical Center - Walnut Creek Campus
Behind the star rating — Deaths: 3 better, 2 the same, 2 worse of 7 measures. Safety: 2 better, 5 the same, 1 worse of 8 measures. Readmissions: 3 better, 5 the same, 2 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 2.01 (1.17 to 2.85) · 2,206 cases | Worse | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 222.42 (177.82 to 267.02) · 120 cases | Worse | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 1.4 (0.91 to 1.9) · 9,764 cases | Worse | Jul 2022 – Jun 2024 |
| SSI - Colon SurgeryInfections | 2.734 | Worse | Oct 2024 – Sep 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.536 | Better | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.341 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.455 | Better | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.245 | Better | Oct 2024 – Sep 2025 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.14 (0.87 to 1.4) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 131 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 10 · 148 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.8 · 695 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 12.5 · 827 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 14.1 · 509 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.4 · 4,483 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.35 (0.18 to 0.53) · 11,630 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.05 to 0.39) · 11,793 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.33 (1.69 to 4.96) · 3,268 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.37 (0 to 2.94) · 1,631 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.76 (1.43 to 4.09) · 3,066 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.12 (0.22 to 12.02) · 1,580 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.43 (1.21 to 7.64) · 1,594 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.82 (0.4 to 3.24) · 685 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.9 · 615 cases | None | Apr 2023 – Mar 2025 |
| SSI - Abdominal HysterectomyInfections | 1.88 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.7 · 93 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.9 · 729 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -30.1 · 91 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -13 · 736 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 34.8 · 842 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.7 · 818 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.3 (3.3 to 8.4) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.8 (7.2 to 15.5) · 28 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 4.9 · 584 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 20.4 · 139 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.9) · 222 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.5) · 321 cases | No different | Jan 2024 – Dec 2024 |
What patients said (758 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 76% |
| Staff "always" explained | 55% |
| Yes, staff "did" give patients this information | 87% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 75% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 69% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 71% |
| Nurses "always" listened carefully | 72% |
| Nurses "always" treated them with courtesy and respect | 83% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 77% |
| Staff "always" explained possible side effects | 42% |
| Yes, staff "did" give patients information about possible symptoms | 87% |
See every measure and the patient survey for Stanford Health Care Tri-Valley
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 2 better, 5 the same, 0 worse of 7 measures. Readmissions: 2 better, 7 the same, 0 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.178 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.237 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.79 (0 to 1.73) · 1,041 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.79 (0.5 to 1.08) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 145.81 (96.5 to 195.12) · 72 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 2.9 · 55 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.6 · 92 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.5 · 96 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 395 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 391 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 10.1 · 162 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3 · 1,736 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.16 (0 to 0.37) · 4,425 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.22 (0.02 to 0.41) · 4,771 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 3.45 (1.46 to 5.44) · 1,403 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0.05 to 2.94) · 645 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 1.81 (0.38 to 3.24) · 1,279 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 8.53 (3.2 to 13.85) · 639 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.15 (1.89 to 8.41) · 648 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.61 (0.14 to 3.07) · 370 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.16 (0 to 0.83) · 4,160 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4 · 74 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.369 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 1.112 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 110 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.1 · 437 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -5.8 · 94 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -19.3 · 456 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -0.3 · 402 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 15.8 · 358 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 6.8 (4.7 to 9.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 10.1 (7.5 to 13.6) · 198 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 80 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.9 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 92 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.4 (9.6 to 16.2) · 1,532 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.8 to 1.2) · 929 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,268 patients answered, 26% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 3 |
| Quietness | 2 |
| Recommend hospital | 4 |
| Room was "always" clean | 65% |
| Nurses "always" communicated well | 77% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 58% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 88% |
| Doctors "always" explained things so they could understand | 74% |
| Doctors "always" listened carefully | 78% |
| Doctors "always" treated them with courtesy and respect | 86% |
| Patients who gave a rating of "9" or "10" (high) | 70% |
| Staff "always" explained new medications | 72% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 74% |
| Nurses "always" treated them with courtesy and respect | 84% |
| "Always" quiet at night | 42% |
| "YES", patients would definitely recommend the hospital | 74% |
| Staff "always" explained possible side effects | 44% |
| Yes, staff "did" give patients information about possible symptoms | 89% |
Original Medicare doctor bills
$860,095
Medicare paid this office $860,095 for 1,329 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 890 | $230,093 | $88 |
| Injection, denosumab, 1 mg | 100 | $190,563 | None |
| Injection, romosozumab-aqqg, 1 mg | 27 | $181,165 | None |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 128 | $41,785 | $59 |
| Short return visit (20+ min) | 451 | $40,330 | $63 |
See all 22 services
| Return visit (30+ min) | 890 | $230,093 | $88 |
| Injection, denosumab, 1 mg | 100 | $190,563 | None |
| Injection, romosozumab-aqqg, 1 mg | 27 | $181,165 | None |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 128 | $41,785 | $59 |
| Short return visit (20+ min) | 451 | $40,330 | $63 |
| New patient visit (45+ min) | 321 | $39,388 | $123 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 95 | $27,922 | $52 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 98 | $26,524 | $48 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 370 | $14,125 | $14 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 64 | $10,029 | $157 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 138 | $8,506 | $28 |
| Injection of drug or substance under skin or into muscle | 135 | $5,474 | $14 |
| Ultrasound scan of head and neck soft tissue | 41 | $4,839 | $105 |
| Long return visit (40+ min) | 33 | $4,829 | $127 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 24 | $3,660 | $146 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 26 | $3,315 | $38 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 18 | $2,497 | $131 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 23 | $2,483 | $46 |
| New patient visit (30+ min) | 36 | $1,900 | $53 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 41 | $867 | $21 |
| Administration of influenza virus vaccine | 15 | $580 | $39 |
| Influenza vaccine, trivalent, split virus, preservative-free, 0.5 ml dosage | 15 | $329 | $22 |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Fine needle aspiration biopsy using ultrasound guidance, first growth | – | – | – | 16 | 12 | 19 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
1,329 Original Medicare patients in 2024. Average age 71 · Under 65 14% · 85 and older 8% · Women 67% · Also on Medicaid 30% · Health risk score 1.28. At or below the middle of the specialty; the typical internal medicine clinician is at 1.76.
Conditions among them: High blood pressure 73% · Diabetes 44% · Chronic kidney disease 26% · Depression 23% · Coronary heart disease 19% · COPD 13% · Heart failure 12% · Cancer 12% · Atrial fibrillation 12% · Stroke 7% · Dementia 5%.
The office billed $2,185,792, Medicare allowed $1,126,529 and paid $860,095; for 47,415 services of 47 kinds; $382,834 of it was for drugs given in the office and $477,261 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,329 | 47,415 | 71 | 1.28 | $2,185,792 | $860,095 |
| 2023 | 1,099 | 21,960 | 71 | 1.31 | $1,655,686 | $615,198 |
| 2022 | 839 | 12,525 | 71 | 1.29 | $1,050,922 | $378,098 |
| 2021 | 443 | 2,905 | 71 | 1.35 | $287,275 | $124,535 |
| 2020 | 506 | 3,181 | 71 | 1.26 | $388,613 | $170,787 |
| 2019 | 393 | 1,546 | 71 | 1.24 | $278,583 | $120,647 |
| 2018 | 546 | 1,906 | 70 | 1.25 | $379,644 | $150,078 |
| 2017 | 404 | 936 | 69 | 1.23 | $222,491 | $82,984 |
| 2016 | 125 | 210 | 68 | 1.44 | $39,480 | $16,908 |
| 2015 | 211 | 238 | 73 | 1.27 | $36,659 | $14,191 |
| 2014 | 300 | 1,651 | 72 | 1.18 | $179,595 | $70,356 |
| 2013 | 81 | 488 | 75 | 1.20 | $50,525 | $21,516 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 20 services
| Return visit (30+ min) | 741 | $198,359 | $87 |
| Injection, denosumab, 1 mg | 87 | $133,199 | None |
| Short return visit (20+ min) | 446 | $47,006 | $63 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 132 | $42,042 | $59 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 106 | $28,523 | $54 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 107 | $26,883 | $47 |
| New patient visit (45+ min) | 212 | $25,537 | $120 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 52 | $8,032 | $154 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 138 | $7,979 | $29 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 52 | $7,398 | $137 |
| Long return visit (40+ min) | 41 | $6,663 | $136 |
| Ultrasound scan of head and neck soft tissue | 37 | $5,099 | $113 |
| Injection of drug or substance under skin or into muscle | 107 | $2,944 | $14 |
| New patient visit (30+ min) | 34 | $2,471 | $73 |
| New patient visit (60+ min) | 14 | $2,430 | $174 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 31 | $2,332 | $38 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 29 | $2,318 | $45 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 12 | $1,530 | $128 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 35 | $682 | $19 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 13 | $155 | $12 |
2022: 18 services
| Return visit (30+ min) | 502 | $110,300 | $97 |
| Injection, denosumab, 1 mg | 70 | $88,102 | None |
| New patient visit (45+ min) | 413 | $51,767 | $125 |
| Short return visit (20+ min) | 218 | $19,051 | $70 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 67 | $15,319 | $56 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 69 | $14,185 | $47 |
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 58 | $11,247 | $58 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 47 | $7,209 | $150 |
| Complex chronic care management services for two or more chronic conditions, first 60 minutes of clinical staff time directed by health care professional, per calendar month | 25 | $4,770 | $126 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 88 | $4,475 | $30 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 44 | $4,147 | $37 |
| Ultrasound scan of head and neck soft tissue | 30 | $3,922 | $115 |
| Long return visit (40+ min) | 22 | $2,975 | $129 |
| New patient visit (30+ min) | 30 | $2,171 | $72 |
| Fine needle aspiration biopsy using ultrasound guidance, first growth | 15 | $2,158 | $135 |
| Injection of drug or substance under skin or into muscle | 79 | $1,842 | $14 |
| Remote monitoring of physiologic parameters, initial set-up and patient education on use of equipment | 56 | $1,049 | $19 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 17 | $1,025 | $43 |
2021: 10 services
| Return visit (30+ min) | 286 | $53,134 | $105 |
| Short return visit (20+ min) | 214 | $23,297 | $71 |
| Injection, denosumab, 1 mg | 14 | $15,732 | None |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 18 | $6,079 | $65 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 19 | $5,213 | $47 |
| New patient visit (45+ min) | 40 | $4,835 | $121 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 49 | $2,980 | $31 |
| Long return visit (40+ min) | 19 | $2,433 | $128 |
| Ultrasound scan of head and neck soft tissue | 12 | $1,396 | $107 |
| Injection of drug or substance under skin or into muscle | 21 | $732 | $12 |
2020: 14 services
| Return visit (30+ min) | 299 | $62,002 | $94 |
| Short return visit (20+ min) | 305 | $43,961 | $66 |
| Injection, denosumab, 1 mg | 18 | $19,730 | None |
| Long return visit (40+ min) | 60 | $13,257 | $134 |
| New patient visit (45+ min) | 67 | $8,678 | $130 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 24 | $3,797 | $158 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 53 | $3,469 | $33 |
| Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | 14 | $2,858 | $204 |
| New patient visit (60+ min) | 13 | $2,450 | $188 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 17 | $2,385 | $140 |
| New patient visit (30+ min) | 15 | $1,313 | $88 |
| Prolonged preventive service(s) (beyond the typical service time of the primary procedure), in the office or other outpatient setting requiring direct patient contact beyond the usual service; first 30 minutes (list separately in addition to code for preve | 16 | $1,211 | $76 |
| Injection of drug or substance under skin or into muscle | 26 | $1,195 | $13 |
| Online digital evaluation and management service for an established patient for up to 7 days, total time 5-10 minutes | 13 | $228 | $14 |
2019: 10 services
| Return visit (30+ min) | 274 | $53,598 | $89 |
| Short return visit (20+ min) | 186 | $23,568 | $62 |
| Long return visit (40+ min) | 68 | $16,702 | $120 |
| New patient visit (45+ min) | 61 | $7,872 | $129 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 31 | $5,055 | $153 |
| Ultrasound scan of head and neck soft tissue | 27 | $3,381 | $113 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 53 | $2,771 | $29 |
| New patient visit (30+ min) | 14 | $1,308 | $93 |
| Injection of drug or substance under skin or into muscle | 11 | $1,175 | $14 |
| Administration of influenza virus vaccine | 14 | $283 | $20 |
2018: 11 services
| Return visit (30+ min) | 356 | $68,700 | $88 |
| Short return visit (20+ min) | 210 | $29,140 | $59 |
| New patient visit (45+ min) | 198 | $21,498 | $109 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 57 | $8,441 | $148 |
| Ultrasound scan of head and neck soft tissue | 39 | $4,589 | $109 |
| Long return visit (40+ min) | 21 | $4,180 | $119 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 73 | $2,885 | $30 |
| Injection of drug or substance under skin or into muscle | 12 | $2,111 | $19 |
| Fine needle aspiration using imaging guidance | 11 | $1,732 | $133 |
| Ultrasonic guidance for needle placement | 11 | $617 | $56 |
| Administration of influenza virus vaccine | 13 | $329 | $25 |
2017: 7 services
| New patient visit (45+ min) | 273 | $36,899 | $135 |
| Return visit (30+ min) | 144 | $20,293 | $86 |
| Short return visit (20+ min) | 129 | $15,353 | $59 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | 38 | $5,838 | $150 |
| Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | 37 | $1,331 | $36 |
| Injection of drug or substance under skin or into muscle | 13 | $1,145 | $24 |
| New patient visit (30+ min) | 15 | $966 | $64 |
2016: 3 services
| Return visit (30+ min) | 46 | $5,674 | $90 |
| Short return visit (20+ min) | 65 | $5,184 | $63 |
| New patient visit (45+ min) | 29 | $4,222 | $146 |
2015: 2 services
| Short return visit (20+ min) | 183 | $11,685 | $61 |
| Return visit (30+ min) | 16 | $1,373 | $86 |
2014: 8 services
| Return visit (30+ min) | 222 | $36,817 | $92 |
| New patient visit (45+ min) | 97 | $13,510 | $139 |
| Injection, denosumab, 1 mg | 11 | $8,668 | None |
| Short return visit (20+ min) | 49 | $3,800 | $63 |
| Long return visit (40+ min) | 18 | $2,559 | $128 |
| Hemoglobin a1c level | 42 | $909 | $13 |
| Blood glucose (sugar) level | 72 | $903 | $5 |
| Injection of drug or substance into vein | 13 | $758 | $54 |
2013: 4 services
| New patient visit (45+ min) | 57 | $7,954 | $140 |
| Return visit (30+ min) | 48 | $6,523 | $95 |
| Hemoglobin a1c level | 27 | $379 | $13 |
| Blood glucose (sugar) level | 38 | $285 | $5 |
Medicaid work
$410,340 in 2024
Medicaid paid $410,340 for 5,978 billed services this clinician did in 2024, up to 238 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Return visit (30+ min) | 2,341 | $179,456 |
| New patient visit (45+ min) | 628 | $70,405 |
| Short return visit (20+ min) | 481 | $39,366 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 589 | $38,008 |
| Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days | 529 | $33,759 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | 510 | $27,464 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; analysis, interpretation and report | 414 | $14,374 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 460 | $4,833 |
| New patient visit (30+ min) | 26 | $2,676 |
| 2024 | 5,978 | 9 | 238 | $410,340 |
| 2023 | 5,099 | 9 | 170 | $328,526 |
| 2022 | 1,022 | 3 | 48 | $101,734 |
| 2021 | 321 | 3 | 31 | $37,510 |
| 2020 | 384 | 3 | 37 | $25,555 |
| 2019 | 42 | 2 | 14 | $5,780 |
| 2018 | 45 | 2 | 19 | $3,837 |
See the largest Medicaid services in earlier years
2023
| Return visit (30+ min) | 1,962 | $143,687 |
| Chronic care management services with the following required elements: multiple (two or more) chronic conditions expected to last at least 12 months, or until the death of the patient, chronic conditions that place the patient at significant risk of death, acute exacerbation/decompensation, or functional decline, comprehensive care plan established, implemented, revised, or monitored; first 20 minutes of clinical staff time directed by a physician or other qualified health care professional, per calendar month. | 761 | $40,797 |
| Short return visit (20+ min) | 569 | $35,430 |
| Remote monitoring of physiologic parameter(s) (eg, weight, blood pressure, pulse oximetry, respiratory flow rate), initial; device(s) supply with daily recording(s) or programmed alert(s) transmission, each 30 days | 571 | $34,787 |
| New patient visit (45+ min) | 277 | $29,931 |
| Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring interactive communication with the patient/caregiver during the month; first 20 minutes | 578 | $27,424 |
| Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; analysis, interpretation and report | 353 | $14,069 |
| New patient visit (30+ min) | 15 | $1,447 |
| Long return visit (40+ min) | 13 | $956 |
2022
| Return visit (30+ min) | 573 | $52,514 |
| New patient visit (45+ min) | 324 | $40,381 |
| Short return visit (20+ min) | 125 | $8,840 |
2021
| Return visit (30+ min) | 146 | $19,404 |
| Short return visit (20+ min) | 163 | $15,950 |
| New patient visit (45+ min) | 12 | $2,156 |
2020
| Short return visit (20+ min) | 262 | $15,135 |
| Return visit (30+ min) | 110 | $8,686 |
| New patient visit (45+ min) | 12 | $1,734 |
2019
| New patient visit (45+ min) | 26 | $4,501 |
| Short return visit (20+ min) | 16 | $1,278 |
2018
| Short return visit (20+ min) | 33 | $2,401 |
| Return visit (30+ min) | 12 | $1,436 |
Drugs they prescribed that Part D paid
$840,203
Pharmacies billed $840,203 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
894 generic and 737 brand-name prescriptions · $840,203 in drug cost · 13 antibiotic prescriptions to 11 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Jardiance | 115 | $161,338 | $1,403 |
| Ozempic | 74 | $117,852 | $1,593 |
| Mounjaro | 53 | $83,219 | $1,570 |
| Trulicity | 47 | $68,873 | $1,465 |
| Tymlos | 18 | $50,529 | $2,807 |
See all 36 drugs
| Jardiance | 115 | $161,338 | $1,403 |
| Ozempic | 74 | $117,852 | $1,593 |
| Mounjaro | 53 | $83,219 | $1,570 |
| Trulicity | 47 | $68,873 | $1,465 |
| Tymlos | 18 | $50,529 | $2,807 |
| Farxiga | 24 | $36,414 | $1,517 |
| Rybelsus | 15 | $36,180 | $2,412 |
| Kerendia | 16 | $29,497 | $1,844 |
| Fiasp Flextouch | 14 | $23,641 | $1,689 |
| Toujeo Max Solostar | 14 | $15,011 | $1,072 |
| Tresiba Flextouch U-200 | 11 | $8,863 | $806 |
| Synthroid | 51 | $5,624 | $110 |
| Novolog Flexpen | 12 | $2,470 | $206 |
| Lantus Solostar | 22 | $2,316 | $105 |
| Lantus | 14 | $2,067 | $148 |
| Levothyroxine | 127 | $2,015 | $16 |
| Ultra-Fine Short Pen Needle | 29 | $1,910 | $66 |
| Metformin Hcl Er | 60 | $1,013 | $17 |
| Ultra-Fine Mini Pen Needle | 14 | $864 | $62 |
| Testosterone Cypionate | 13 | $764 | $59 |
| Rosuvastatin | 47 | $707 | $15 |
| Glimepiride | 23 | $513 | $22 |
| Alendronate | 39 | $485 | $12 |
| Atorvastatin | 54 | $417 | $8 |
| Metformin | 42 | $399 | $10 |
| Lisinopril | 42 | $385 | $9 |
| Spironolactone | 18 | $378 | $21 |
| Amlodipine Besylate | 35 | $329 | $9 |
| Losartan | 31 | $245 | $8 |
| Methimazole | 24 | $181 | $8 |
| Benazepril | 11 | $148 | $13 |
| Pioglitazone | 14 | $103 | $7 |
| Norgestimate-Ethinyl Estradiol | 13 | $87 | $7 |
| Hydrochlorothiazide | 12 | $70 | $6 |
| Zolpidem | 12 | $35 | $3 |
| Amitriptyline | 11 | $24 | $2 |
Year by year
| 2024 | 1,709 | 420 | None | 43% | $840,203 |
| 2023 | 1,738 | 416 | None | 42% | $972,844 |
| 2022 | 2,049 | 405 | None | 37% | $857,372 |
| 2021 | 2,265 | 448 | 1% (15) | 35% | $807,148 |
| 2020 | 3,792 | 453 | None | 35% | $1,203,280 |
| 2019 | 3,925 | 517 | None | 39% | $1,168,729 |
| 2018 | 4,407 | 578 | None | 38% | $1,039,169 |
| 2017 | 1,621 | 309 | 2% (30) | 37% | $329,465 |
| 2016 | 375 | 99 | 12% (43) | 39% | $61,666 |
| 2015 | 687 | 288 | 4% (25) | 36% | $124,043 |
| 2014 | 1,089 | 288 | None | 38% | $154,552 |
| 2013 | 537 | 154 | None | 43% | $94,961 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 39 drugs
| Forteo | 30 | $140,507 | $4,684 |
| Jardiance | 68 | $110,015 | $1,618 |
| Trulicity | 51 | $103,884 | $2,037 |
| Ozempic | 45 | $80,671 | $1,793 |
| Farxiga | 33 | $57,078 | $1,730 |
| Novolog Flexpen | 27 | $47,022 | $1,742 |
| Tresiba Flextouch U-200 | 28 | $42,722 | $1,526 |
| Mounjaro | 25 | $42,374 | $1,695 |
| Januvia | 21 | $31,640 | $1,507 |
| Toujeo Max Solostar | 19 | $19,146 | $1,008 |
| Novolog | 16 | $15,400 | $963 |
| Lantus | 21 | $13,419 | $639 |
| Lantus Solostar | 21 | $12,920 | $615 |
| Testosterone | 20 | $10,326 | $516 |
| Toujeo Solostar | 15 | $7,449 | $497 |
| Basaglar Kwikpen U-100 | 17 | $6,500 | $382 |
| Insulin Lispro Kwikpen U-100 | 12 | $6,228 | $519 |
| Synthroid | 41 | $5,478 | $134 |
| Vascepa | 11 | $4,171 | $379 |
| Levothyroxine | 161 | $3,039 | $19 |
| Nano 2nd Gen Pen Needle | 16 | $2,116 | $132 |
| Ultra-Fine Short Pen Needle | 13 | $1,745 | $134 |
| Metformin Hcl Er | 81 | $1,312 | $16 |
| Atorvastatin | 71 | $1,242 | $17 |
| Ulticare Pen Needle | 13 | $1,178 | $91 |
| Rosuvastatin | 38 | $919 | $24 |
| Methimazole | 34 | $756 | $22 |
| Pioglitazone | 20 | $588 | $29 |
| Metformin | 40 | $585 | $15 |
| Lisinopril | 42 | $560 | $13 |
| Amlodipine Besylate | 30 | $503 | $17 |
| Alendronate | 34 | $477 | $14 |
| Glimepiride | 14 | $406 | $29 |
| Losartan | 12 | $384 | $32 |
| Liothyronine | 14 | $335 | $24 |
| Pravastatin | 14 | $317 | $23 |
| Triamterene-Hydrochlorothiazid | 11 | $204 | $19 |
| Hydrochlorothiazide | 22 | $168 | $8 |
| Finasteride | 12 | $62 | $5 |
2022: 47 drugs
| Jardiance | 96 | $144,686 | $1,507 |
| Trulicity | 77 | $111,009 | $1,442 |
| Forteo | 15 | $86,681 | $5,779 |
| Novolog Flexpen | 21 | $39,588 | $1,885 |
| Ozempic | 18 | $35,369 | $1,965 |
| Januvia | 18 | $28,926 | $1,607 |
| Toujeo Max Solostar | 17 | $25,537 | $1,502 |
| Tradjenta | 33 | $20,017 | $607 |
| Lantus Solostar | 26 | $16,555 | $637 |
| Tresiba Flextouch U-200 | 12 | $16,379 | $1,365 |
| Tresiba Flextouch U-100 | 20 | $15,300 | $765 |
| Testosterone | 39 | $13,658 | $350 |
| Lantus | 18 | $13,038 | $724 |
| Humalog Kwikpen U-100 | 14 | $13,000 | $929 |
| Insulin Lispro Kwikpen U-100 | 18 | $7,788 | $433 |
| Synthroid | 71 | $6,866 | $97 |
| Tirosint | 11 | $2,900 | $264 |
| Levothyroxine | 184 | $2,797 | $15 |
| Nano 2nd Gen Pen Needle | 18 | $2,331 | $130 |
| Ultra-Fine Short Pen Needle | 20 | $2,196 | $110 |
| Ultra-Fine Mini Pen Needle | 12 | $1,263 | $105 |
| Atorvastatin | 83 | $1,169 | $14 |
| Metformin Hcl Er | 86 | $1,004 | $12 |
| Ezetimibe | 20 | $916 | $46 |
| Liothyronine | 17 | $712 | $42 |
| Rosuvastatin | 30 | $710 | $24 |
| Testosterone Cypionate | 17 | $696 | $41 |
| Lisinopril | 60 | $671 | $11 |
| Metformin | 60 | $658 | $11 |
| Chlorthalidone | 16 | $571 | $36 |
| Gabapentin | 15 | $483 | $32 |
| Alendronate | 42 | $460 | $11 |
| Pioglitazone | 26 | $451 | $17 |
| Methimazole | 25 | $265 | $11 |
| Hydrochlorothiazide | 39 | $258 | $7 |
| Glimepiride | 12 | $251 | $21 |
| Finasteride | 17 | $242 | $14 |
| Amlodipine Besylate | 39 | $230 | $6 |
| Metoprolol | 30 | $224 | $7 |
| Glipizide | 12 | $184 | $15 |
| Losartan | 21 | $183 | $9 |
| Amiodarone | 13 | $148 | $11 |
| Metoprolol | 11 | $148 | $13 |
| Simvastatin | 22 | $125 | $6 |
| Pantoprazole | 15 | $104 | $7 |
| Omeprazole | 14 | $99 | $7 |
| Atenolol | 12 | $62 | $5 |
2021: 53 drugs
| Trulicity | 70 | $107,064 | $1,529 |
| Jardiance | 78 | $79,367 | $1,018 |
| Victoza 3-Pak | 19 | $41,923 | $2,206 |
| Tresiba Flextouch U-200 | 25 | $37,453 | $1,498 |
| Tymlos | 16 | $36,206 | $2,263 |
| Humalog Kwikpen U-100 | 31 | $33,659 | $1,086 |
| Lantus Solostar | 36 | $25,766 | $716 |
| Novolog Flexpen | 19 | $25,250 | $1,329 |
| Ozempic | 15 | $21,432 | $1,429 |
| Toujeo Max Solostar | 12 | $20,897 | $1,741 |
| Januvia | 24 | $19,013 | $792 |
| Farxiga | 13 | $14,347 | $1,104 |
| Toujeo Solostar | 28 | $14,027 | $501 |
| Novolog | 12 | $13,789 | $1,149 |
| Humalog | 15 | $10,846 | $723 |
| Lantus | 17 | $9,572 | $563 |
| Basaglar Kwikpen U-100 | 17 | $8,631 | $508 |
| Testosterone | 19 | $6,068 | $319 |
| Tresiba Flextouch U-100 | 11 | $5,920 | $538 |
| Levothyroxine | 190 | $3,905 | $21 |
| Synthroid | 47 | $3,483 | $74 |
| Nano 2nd Gen Pen Needle | 26 | $3,056 | $118 |
| Liothyronine | 29 | $2,422 | $84 |
| Atorvastatin | 123 | $1,726 | $14 |
| Testosterone Cypionate | 28 | $1,562 | $56 |
| Fenofibrate | 16 | $1,416 | $88 |
| Rosuvastatin | 20 | $1,398 | $70 |
| Ultra-Fine Short Pen Needle | 13 | $1,211 | $93 |
| Estradiol | 12 | $990 | $83 |
| Ultra-Fine Mini Pen Needle | 12 | $942 | $78 |
| Methimazole | 44 | $854 | $19 |
| Metformin Hcl Er | 51 | $731 | $14 |
| Hydrocortisone | 12 | $710 | $59 |
| Nifedipine Er | 12 | $636 | $53 |
| Chlorthalidone | 19 | $616 | $32 |
| Pioglitazone | 30 | $609 | $20 |
| Metformin | 83 | $495 | $6 |
| Lisinopril | 74 | $464 | $6 |
| Alendronate | 48 | $417 | $9 |
| Omeprazole | 32 | $397 | $12 |
| Metoprolol | 16 | $378 | $24 |
| Venlafaxine Hcl Er | 11 | $376 | $34 |
| Glipizide Er | 15 | $355 | $24 |
| Glimepiride | 21 | $324 | $15 |
| Levetiracetam | 13 | $312 | $24 |
| Simvastatin | 33 | $309 | $9 |
| Losartan | 22 | $306 | $14 |
| Tamsulosin | 14 | $295 | $21 |
| Amlodipine Besylate | 53 | $285 | $5 |
| Gabapentin | 16 | $269 | $17 |
| Hydrochlorothiazide | 36 | $215 | $6 |
| Metoprolol | 29 | $186 | $6 |
| Carvedilol | 12 | $75 | $6 |
2020: 83 drugs
| Trulicity | 105 | $133,133 | $1,268 |
| Jardiance | 147 | $122,844 | $836 |
| Victoza 3-Pak | 54 | $79,147 | $1,466 |
| Tresiba Flextouch U-200 | 27 | $56,108 | $2,078 |
| Novolog Flexpen | 44 | $53,019 | $1,205 |
| Lantus Solostar | 63 | $46,345 | $736 |
| Humalog Kwikpen U-100 | 41 | $42,005 | $1,025 |
| Januvia | 45 | $35,828 | $796 |
| Farxiga | 34 | $29,435 | $866 |
| Lantus | 43 | $28,328 | $659 |
| Symlinpen 120 | 22 | $25,819 | $1,174 |
| Genotropin | 12 | $24,742 | $2,062 |
| Toujeo Solostar | 34 | $23,032 | $677 |
| Humalog | 32 | $21,648 | $676 |
| Tradjenta | 24 | $20,573 | $857 |
| Basaglar Kwikpen U-100 | 23 | $19,301 | $839 |
| Ozempic | 17 | $18,746 | $1,103 |
| Tresiba Flextouch U-100 | 19 | $16,194 | $852 |
| Invokana | 11 | $14,539 | $1,322 |
| Janumet | 11 | $12,733 | $1,158 |
| Testosterone | 40 | $11,554 | $289 |
| Glyxambi | 15 | $10,669 | $711 |
| Levothyroxine | 297 | $6,968 | $23 |
| Insulin Lispro Kwikpen U-100 | 14 | $6,649 | $475 |
| Levemir Flextouch | 12 | $5,829 | $486 |
| Symbicort | 12 | $5,156 | $430 |
| Synthroid | 61 | $4,667 | $77 |
| Ultra-Fine Nano Pen Needle | 50 | $4,308 | $86 |
| Tirosint | 18 | $4,275 | $237 |
| Vascepa | 11 | $3,774 | $343 |
| Ultra-Fine Short Pen Needle | 31 | $3,401 | $110 |
| Atorvastatin | 176 | $2,922 | $17 |
| Liothyronine | 47 | $2,858 | $61 |
| Febuxostat | 11 | $2,701 | $246 |
| Testosterone Cypionate | 50 | $2,178 | $44 |
| Rosuvastatin | 51 | $1,916 | $38 |
| Metformin Hcl Er | 113 | $1,831 | $16 |
| Raloxifene | 13 | $1,751 | $135 |
| Metformin | 155 | $1,525 | $10 |
| Niacin Er | 16 | $1,512 | $94 |
| Solifenacin | 13 | $1,186 | $91 |
| Fenofibrate | 16 | $1,182 | $74 |
| Olmesartan Medoxomil | 21 | $1,152 | $55 |
| Repaglinide | 11 | $1,145 | $104 |
| Hydrocortisone | 16 | $1,096 | $69 |
| Albuterol Sulfate Hfa | 18 | $976 | $54 |
| Lisinopril | 120 | $850 | $7 |
| Glipizide Er | 37 | $826 | $22 |
| Pioglitazone | 49 | $823 | $17 |
| Losartan-Hydrochlorothiazide | 11 | $811 | $74 |
| Omeprazole | 40 | $786 | $20 |
| Ultra-Fine Mini Pen Needle | 16 | $751 | $47 |
| Amlodipine Besylate | 102 | $694 | $7 |
| Ezetimibe | 13 | $692 | $53 |
| Fenofibrate | 14 | $661 | $47 |
| Novofine 32 | 11 | $658 | $60 |
| Venlafaxine Hcl Er | 14 | $627 | $45 |
| Methimazole | 32 | $578 | $18 |
| Losartan | 38 | $572 | $15 |
| Metoprolol | 22 | $534 | $24 |
| Simvastatin | 39 | $508 | $13 |
| Alendronate | 41 | $410 | $10 |
| Prednisone | 13 | $381 | $29 |
| Pantoprazole | 22 | $361 | $16 |
| Hydrochlorothiazide | 65 | $353 | $5 |
| Gabapentin | 18 | $328 | $18 |
| Tamsulosin | 17 | $317 | $19 |
| Glimepiride | 34 | $305 | $9 |
| Levetiracetam | 12 | $281 | $23 |
| Chlorthalidone | 14 | $276 | $20 |
| Enalapril Maleate | 11 | $237 | $22 |
| Probenecid | 12 | $233 | $19 |
| Metoprolol | 38 | $230 | $6 |
| Lovastatin | 20 | $193 | $10 |
| Naproxen | 12 | $183 | $15 |
| Zolpidem | 12 | $152 | $13 |
| Acyclovir | 15 | $142 | $9 |
| Fluoxetine | 17 | $136 | $8 |
| Atenolol | 22 | $131 | $6 |
| Carvedilol | 27 | $128 | $5 |
| Trazodone | 16 | $63 | $4 |
| Alprazolam | 16 | $57 | $4 |
| Dexamethasone | 14 | $54 | $4 |
2019: 75 drugs
| Trulicity | 128 | $156,305 | $1,221 |
| Victoza 3-Pak | 78 | $110,191 | $1,413 |
| Jardiance | 127 | $93,738 | $738 |
| Humalog Kwikpen U-100 | 69 | $58,216 | $844 |
| Novolog Flexpen | 54 | $51,073 | $946 |
| Tresiba Flextouch U-200 | 34 | $49,963 | $1,470 |
| Humalog | 53 | $44,049 | $831 |
| Lantus Solostar | 63 | $42,207 | $670 |
| Forteo | 11 | $40,729 | $3,703 |
| Lantus | 36 | $31,936 | $887 |
| Toujeo Solostar | 54 | $30,896 | $572 |
| Januvia | 37 | $30,378 | $821 |
| Tradjenta | 18 | $22,283 | $1,238 |
| Farxiga | 35 | $22,230 | $635 |
| Tresiba Flextouch U-100 | 37 | $21,918 | $592 |
| Invokana | 21 | $16,939 | $807 |
| Testosterone | 31 | $13,764 | $444 |
| Levemir Flextouch | 24 | $13,374 | $557 |
| Janumet | 14 | $11,534 | $824 |
| Glyxambi | 15 | $10,287 | $686 |
| Novolog | 16 | $9,660 | $604 |
| Levothyroxine | 438 | $9,404 | $21 |
| Basaglar Kwikpen U-100 | 15 | $9,364 | $624 |
| Janumet Xr | 11 | $8,330 | $757 |
| Tirosint | 41 | $8,134 | $198 |
| Synthroid | 86 | $6,178 | $72 |
| Ultra-Fine Short Pen Needle | 40 | $3,775 | $94 |
| Ultra-Fine Nano Pen Needle | 55 | $3,608 | $66 |
| Atorvastatin | 173 | $3,120 | $18 |
| Liothyronine | 58 | $2,964 | $51 |
| Metformin Hcl Er | 155 | $2,549 | $16 |
| Testosterone Cypionate | 42 | $1,994 | $47 |
| Armour Thyroid | 26 | $1,940 | $75 |
| Rosuvastatin | 38 | $1,723 | $45 |
| Ultra-Fine Mini Pen Needle | 30 | $1,668 | $56 |
| Metformin | 168 | $1,399 | $8 |
| Niacin Er | 12 | $1,170 | $98 |
| Venlafaxine Hcl Er | 25 | $1,102 | $44 |
| Losartan | 59 | $982 | $17 |
| Estradiol | 22 | $977 | $44 |
| Lisinopril | 114 | $965 | $8 |
| Ventolin Hfa | 17 | $954 | $56 |
| Fenofibrate | 23 | $924 | $40 |
| Amlodipine Besylate | 107 | $910 | $9 |
| Methimazole | 33 | $704 | $21 |
| Insulin | 11 | $613 | $56 |
| Pantoprazole | 37 | $603 | $16 |
| Oxybutynin Chloride Er | 11 | $599 | $54 |
| Glipizide Er | 22 | $580 | $26 |
| Metoprolol | 22 | $548 | $25 |
| Gabapentin | 20 | $539 | $27 |
| Olopatadine | 13 | $468 | $36 |
| Simvastatin | 41 | $414 | $10 |
| Glimepiride | 34 | $393 | $12 |
| Pravastatin | 16 | $390 | $24 |
| Easy Touch Pen Needle | 12 | $348 | $29 |
| Losartan-Hydrochlorothiazide | 24 | $346 | $14 |
| Pioglitazone | 21 | $346 | $16 |
| Enalapril Maleate | 12 | $320 | $27 |
| Hydrochlorothiazide | 46 | $295 | $6 |
| Omeprazole | 19 | $291 | $15 |
| Zolpidem | 18 | $285 | $16 |
| Carvedilol | 22 | $223 | $10 |
| Tamsulosin | 14 | $217 | $16 |
| Probenecid | 11 | $208 | $19 |
| Escitalopram | 11 | $206 | $19 |
| Lovastatin | 14 | $197 | $14 |
| Atenolol | 17 | $187 | $11 |
| Glipizide | 26 | $166 | $6 |
| Ramipril | 17 | $151 | $9 |
| Alendronate | 12 | $148 | $12 |
| Benazepril | 11 | $148 | $13 |
| Spironolactone | 15 | $141 | $9 |
| Metoprolol | 11 | $107 | $10 |
| Dexamethasone | 15 | $73 | $5 |
2018: 88 drugs
| Victoza 3-Pak | 73 | $100,459 | $1,376 |
| Trulicity | 95 | $85,877 | $904 |
| Novolog Flexpen | 77 | $64,665 | $840 |
| Lantus Solostar | 96 | $42,989 | $448 |
| Lantus | 54 | $40,760 | $755 |
| Humalog Kwikpen U-100 | 46 | $37,549 | $816 |
| Tresiba Flextouch U-200 | 35 | $35,256 | $1,007 |
| Novolog | 40 | $34,891 | $872 |
| Jardiance | 53 | $34,863 | $658 |
| Humalog | 50 | $30,299 | $606 |
| Victoza 2-Pak | 40 | $29,765 | $744 |
| Januvia | 47 | $28,865 | $614 |
| Toujeo Solostar | 52 | $28,788 | $554 |
| Invokana | 26 | $22,385 | $861 |
| Tradjenta | 22 | $17,370 | $790 |
| Androgel | 17 | $17,351 | $1,021 |
| Levemir Flextouch | 26 | $17,141 | $659 |
| Farxiga | 29 | $14,134 | $487 |
| Tresiba Flextouch U-100 | 28 | $13,829 | $494 |
| Tirosint | 74 | $13,191 | $178 |
| Tanzeum | 20 | $11,513 | $576 |
| Levothyroxine | 494 | $10,696 | $22 |
| Lyrica | 15 | $9,132 | $609 |
| Vesicare | 16 | $8,818 | $551 |
| Janumet Xr | 12 | $8,217 | $685 |
| Synthroid | 133 | $7,833 | $59 |
| Uloric | 18 | $7,733 | $430 |
| Testosterone | 20 | $6,842 | $342 |
| Liothyronine | 104 | $5,583 | $54 |
| Basaglar Kwikpen U-100 | 16 | $5,222 | $326 |
| Repaglinide | 20 | $5,203 | $260 |
| Ultra-Fine Short Pen Needle | 53 | $4,271 | $81 |
| Rosuvastatin | 48 | $3,234 | $67 |
| Atorvastatin | 148 | $2,659 | $18 |
| Metformin Hcl Er | 155 | $2,453 | $16 |
| Ultra-Fine Nano Pen Needle | 46 | $2,185 | $47 |
| Estradiol | 41 | $2,146 | $52 |
| Hydrocortisone | 27 | $1,994 | $74 |
| Gabapentin | 53 | $1,886 | $36 |
| Niacin Er | 20 | $1,826 | $91 |
| Fenofibrate | 12 | $1,620 | $135 |
| Ultra-Fine Mini Pen Needle | 29 | $1,581 | $55 |
| Duloxetine | 12 | $1,513 | $126 |
| Armour Thyroid | 20 | $1,472 | $74 |
| Testosterone Cypionate | 32 | $1,359 | $42 |
| Venlafaxine Hcl Er | 37 | $1,258 | $34 |
| Metformin | 175 | $1,244 | $7 |
| Insulin | 25 | $1,092 | $44 |
| Ventolin Hfa | 18 | $993 | $55 |
| Losartan | 87 | $916 | $11 |
| Glimepiride | 51 | $819 | $16 |
| Oxybutynin Chloride Er | 14 | $816 | $58 |
| Methimazole | 44 | $756 | $17 |
| Novofine 32 | 12 | $739 | $62 |
| Fenofibrate | 20 | $727 | $36 |
| Amlodipine Besylate | 112 | $722 | $6 |
| Escitalopram | 11 | $657 | $60 |
| Pravastatin | 23 | $626 | $27 |
| Levoxyl | 11 | $533 | $48 |
| Lisinopril | 88 | $530 | $6 |
| Triazolam | 15 | $493 | $33 |
| Tamsulosin | 15 | $490 | $33 |
| Pioglitazone | 37 | $444 | $12 |
| Pantoprazole | 34 | $399 | $12 |
| Metoprolol | 15 | $354 | $24 |
| Irbesartan | 17 | $353 | $21 |
| Glipizide Er | 23 | $353 | $15 |
| Zolpidem | 24 | $295 | $12 |
| Hydrochlorothiazide | 34 | $282 | $8 |
| Enalapril Maleate | 19 | $275 | $14 |
| Simvastatin | 33 | $271 | $8 |
| Acyclovir | 14 | $262 | $19 |
| Losartan-Hydrochlorothiazide | 20 | $247 | $12 |
| Metoprolol | 17 | $237 | $14 |
| Benazepril | 24 | $230 | $10 |
| Allopurinol | 15 | $219 | $15 |
| Finasteride | 13 | $213 | $16 |
| Fluoxetine | 12 | $202 | $17 |
| Potassium Chloride | 11 | $202 | $18 |
| Spironolactone | 11 | $199 | $18 |
| Atenolol | 20 | $172 | $9 |
| Sertraline | 16 | $166 | $10 |
| Lovastatin | 20 | $149 | $7 |
| Omeprazole | 24 | $147 | $6 |
| Carvedilol | 18 | $144 | $8 |
| Glipizide | 21 | $142 | $7 |
| Ramipril | 12 | $131 | $11 |
| Dexamethasone | 11 | $74 | $7 |
2017: 42 drugs
| Lantus Solostar | 63 | $28,179 | $447 |
| Victoza 3-Pak | 19 | $23,192 | $1,221 |
| Humalog Kwikpen U-100 | 16 | $15,405 | $963 |
| Novolog Flexpen | 26 | $14,417 | $555 |
| Trulicity | 14 | $14,327 | $1,023 |
| Humulin R U-500 Kwikpen | 14 | $11,811 | $844 |
| Januvia | 27 | $11,591 | $429 |
| Tanzeum | 21 | $10,961 | $522 |
| Invokana | 22 | $10,901 | $495 |
| Metformin Hcl Er | 32 | $7,249 | $227 |
| Lyrica | 14 | $5,711 | $408 |
| Levemir Flextouch | 14 | $5,711 | $408 |
| Jardiance | 12 | $5,263 | $439 |
| Invokamet | 11 | $4,719 | $429 |
| Levothyroxine | 138 | $3,252 | $24 |
| Aripiprazole | 12 | $2,595 | $216 |
| Tirosint | 14 | $2,151 | $154 |
| Synthroid | 26 | $1,136 | $44 |
| Liothyronine | 24 | $1,002 | $42 |
| Rosuvastatin | 19 | $895 | $47 |
| Ventolin Hfa | 16 | $849 | $53 |
| Atorvastatin | 64 | $842 | $13 |
| Ultra-Fine Short Pen Needle | 11 | $747 | $68 |
| Estradiol | 21 | $720 | $34 |
| Metformin | 63 | $432 | $7 |
| Gabapentin | 19 | $377 | $20 |
| Amlodipine Besylate | 63 | $357 | $6 |
| Insulin | 12 | $354 | $30 |
| Hydrocodone-Acetaminophen | 17 | $248 | $15 |
| Pioglitazone | 25 | $244 | $10 |
| Lisinopril | 42 | $186 | $4 |
| Losartan | 22 | $179 | $8 |
| Zolpidem | 17 | $159 | $9 |
| Pravastatin | 12 | $157 | $13 |
| Methimazole | 15 | $130 | $9 |
| Clonazepam | 24 | $117 | $5 |
| Alprazolam | 19 | $95 | $5 |
| Hydrochlorothiazide | 11 | $86 | $8 |
| Furosemide | 11 | $72 | $7 |
| Citalopram Hbr | 15 | $66 | $4 |
| Alendronate | 12 | $57 | $5 |
| Lorazepam | 11 | $44 | $4 |
2016: 8 drugs
| Novolog Flexpen | 13 | $6,867 | $528 |
| Invokana | 17 | $6,624 | $390 |
| Jardiance | 16 | $6,148 | $384 |
| Levothyroxine | 37 | $1,167 | $32 |
| Hydrocodone-Acetaminophen | 28 | $983 | $35 |
| Alprazolam | 19 | $253 | $13 |
| Lorazepam | 16 | $124 | $8 |
| Zolpidem | 12 | $105 | $9 |
2015: 18 drugs
| Lantus Solostar | 30 | $17,916 | $597 |
| Novolog Flexpen | 15 | $9,916 | $661 |
| Novolog | 16 | $9,554 | $597 |
| Humalog Kwikpen U-100 | 11 | $7,903 | $718 |
| Januvia | 15 | $6,749 | $450 |
| Invokana | 18 | $6,353 | $353 |
| Levothyroxine | 78 | $1,976 | $25 |
| Bd Ultra-Fine Pen Needle | 14 | $962 | $69 |
| Synthroid | 21 | $845 | $40 |
| Metformin Hcl Er | 14 | $438 | $31 |
| Metformin | 19 | $236 | $12 |
| Hydrocodone-Acetaminophen | 13 | $145 | $11 |
| Azithromycin | 17 | $123 | $7 |
| Glimepiride | 17 | $123 | $7 |
| Cephalexin | 19 | $111 | $6 |
| Lorazepam | 12 | $97 | $8 |
| Amlodipine Besylate | 11 | $89 | $8 |
| Ciprofloxacin | 18 | $89 | $5 |
2014: 22 drugs
| Lantus Solostar | 58 | $29,140 | $502 |
| Januvia | 42 | $17,041 | $406 |
| Novolog Flexpen | 19 | $10,401 | $547 |
| Janumet | 25 | $10,359 | $414 |
| Novolog | 13 | $6,132 | $472 |
| Invokana | 15 | $5,738 | $383 |
| Humalog | 12 | $5,592 | $466 |
| Lantus | 17 | $4,753 | $280 |
| Crestor | 12 | $2,266 | $189 |
| Levothyroxine | 114 | $2,259 | $20 |
| Bd Ultra-Fine Pen Needle | 51 | $2,229 | $44 |
| Synthroid | 30 | $1,567 | $52 |
| Metformin | 102 | $991 | $10 |
| Metformin Hcl Er | 22 | $958 | $44 |
| Alendronate | 43 | $358 | $8 |
| Methimazole | 42 | $327 | $8 |
| Atorvastatin | 14 | $300 | $21 |
| Amlodipine Besylate | 26 | $206 | $8 |
| Simvastatin | 14 | $193 | $14 |
| Lisinopril | 24 | $186 | $8 |
| Glimepiride | 17 | $146 | $9 |
| Hydrochlorothiazide | 27 | $115 | $4 |
2013: 13 drugs
| Levemir | 16 | $14,479 | $905 |
| Novolog Flexpen | 21 | $9,597 | $457 |
| Januvia | 21 | $8,258 | $393 |
| Lantus Solostar | 22 | $7,645 | $348 |
| Novolog | 12 | $7,144 | $595 |
| Lantus | 18 | $4,274 | $237 |
| Janumet | 13 | $3,439 | $265 |
| Bd Ultra-Fine Pen Needle | 29 | $1,317 | $45 |
| Metformin | 56 | $738 | $13 |
| Atorvastatin | 27 | $614 | $23 |
| Hydrocortisone | 14 | $514 | $37 |
| Levothyroxine | 33 | $396 | $12 |
| Lisinopril | 13 | $134 | $10 |
Money from drug and device companies
$1,414 in 2025
| 2025 | 28 | 69 | None | $1,414 |
| 2024 | 18 | 54 | None | $1,156 |
| 2023 | 19 | 55 | None | $1,176 |
| 2022 | 18 | 51 | None | $866 |
| 2021 | 10 | 21 | None | $473 |
| 2020 | 8 | 16 | None | $501 |
| 2019 | 10 | 27 | None | $504 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Amgen | Evenity | $306 | 18 payments
|
| Lilly USA | Mounjaro | $102 | 7 payments
|
| Exact Sciences | Cologuard Collection Kit | $83 | 3 payments
|
| Sanofi-Aventis U.S. | Tzield | $80 | 3 payments
|
| Alexion Pharmaceuticals | Strensiq | $61 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $58 | 3 payments
|
See all 67 published payments
| Amgen | Meals · 2025-12-10 | Evenity | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-12-04 | Jardiance | $16 |
| Novo Nordisk | Meals · 2025-12-03 | Rybelsus | $17 |
| Madrigal Pharmaceuticals | Meals · 2025-12-01 | Rezdiffra | $14 |
| Organon | Meals · 2025-11-25 | None | $19 |
| Exact Sciences | Meals · 2025-11-19 | Cologuard Collection Kit | $25 |
| Amgen | Meals · 2025-11-10 | Tepezza | $2 |
| Astellas Pharma US | Meals · 2025-11-03 | Veozah | $19 |
| Amgen | Meals · 2025-10-31 | Evenity | $3 |
| Amgen | Meals · 2025-10-29 | Evenity | $27 |
| Ascendis Pharma Endocrinology | Meals · 2025-10-22 | Yorvipath | $30 |
| Amgen | Meals · 2025-10-21 | Evenity | $5 |
| Amgen | Meals · 2025-10-15 | Tepezza | $22 |
| Amgen | Meals · 2025-10-14 | Evenity | $5 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-10-08 | Kerendia | $16 |
| ARS Pharmaceuticals Operations | Meals · 2025-10-06 | Neffy | $24 |
| Lilly USA | Meals · 2025-10-03 | Mounjaro | $20 |
| Antares Pharma | Meals · 2025-10-02 | Xyosted | $15 |
| Medtronic | Meals · 2025-10-01 | Minimed 780g | $17 |
| Amgen | Meals · 2025-09-25 | Tepezza | $2 |
| Amgen | Meals · 2025-09-24 | Evenity | $18 |
| Alexion Pharmaceuticals | Meals · 2025-09-17 | Strensiq | $33 |
| Radius Health | Meals · 2025-09-16 | Tymlos | $32 |
| Amgen | Meals · 2025-09-10 | Tepezza | $19 |
| Madrigal Pharmaceuticals | Meals · 2025-09-09 | Rezdiffra | $16 |
| Madrigal Pharmaceuticals | Meals · 2025-09-09 | Rezdiffra | $16 |
| Fresenius Kabi USA | Meals · 2025-09-03 | None | $35 |
| Ascendis Pharma Endocrinology | Meals · 2025-08-27 | Yorvipath | $28 |
| Neurocrine BioSciences | Meals · 2025-08-14 | Crenessity | $22 |
| Lilly USA | Meals · 2025-08-05 | Mounjaro | $11 |
| Esperion Therapeutics | Meals · 2025-07-30 | Nexletol | $29 |
| Astellas Pharma US | Meals · 2025-07-23 | Veozah | $23 |
| Lilly USA | Meals · 2025-07-22 | Zepbound | $11 |
| Lilly USA | Meals · 2025-07-16 | Zepbound | $10 |
| GlaxoSmithKline | Meals · 2025-07-16 | Shingrix | $23 |
| Amgen | Meals · 2025-07-09 | Tepezza | $22 |
| Beta Bionics | Meals · 2025-07-07 | Ilet Bionic Pancreas | $32 |
| Amgen | Meals · 2025-06-18 | Evenity | $19 |
| Abbott Laboratories | Meals · 2025-06-13 | Freestyle Libre 3 | $24 |
| Novo Nordisk | Meals · 2025-06-04 | Wegovy | $29 |
| Exact Sciences | Meals · 2025-06-04 | Cologuard Collection Kit | $28 |
| Sanofi-Aventis U.S. | Meals · 2025-05-28 | Tzield | $35 |
| Novartis Pharmaceuticals | Meals · 2025-05-23 | Leqvio | $31 |
| Lilly USA | Meals · 2025-05-21 | Zepbound | $25 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-05-14 | Jardiance | $15 |
| Amgen | Meals · 2025-05-12 | Evenity | $24 |
| Lilly USA | Meals · 2025-05-07 | Mounjaro | $11 |
| Averitas Pharma | Meals · 2025-04-30 | Qutenza | $29 |
| Genentech USA | Meals · 2025-04-23 | Xolair | $23 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-04-21 | Kerendia | $16 |
| Amgen | Meals · 2025-04-09 | Evenity | $23 |
| Amgen | Meals · 2025-04-02 | Tepezza | $27 |
| Sanofi-Aventis U.S. | Meals · 2025-03-19 | Tzield | $25 |
| Globus Medical | Meals · 2025-03-10 | Senza | $31 |
| Amgen | Meals · 2025-02-28 | Evenity | $19 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-26 | Jardiance | $19 |
| Bayer Healthcare Pharmaceuticals | Meals · 2025-02-20 | Kerendia | $26 |
| Sanofi-Aventis U.S. | Meals · 2025-02-10 | Tzield | $20 |
| Amgen | Meals · 2025-02-05 | Tepezza | $22 |
| Novartis Pharmaceuticals | Meals · 2025-01-30 | Leqvio | $21 |
| Exact Sciences | Meals · 2025-01-29 | Cologuard Collection Kit | $30 |
| Alexion Pharmaceuticals | Meals · 2025-01-22 | Strensiq | $28 |
| Neurocrine BioSciences | Meals · 2025-01-22 | Crenessity | $23 |
| Xeris Pharmaceuticals | Meals · 2025-01-20 | Gvoke Hypopen | $21 |
| Amgen | Meals · 2025-01-15 | Evenity | $27 |
| Lilly USA | Meals · 2025-01-09 | Mounjaro | $13 |
| Dexcom | Meals · 2025-01-06 | Dexcom G6 Transmitter | $30 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $1,156
| Amgen | Evenity | $222 | 11 payments
|
| Astellas Pharma US | Veozah | $156 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $120 | 7 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $90 | 4 payments
|
| Lilly USA | Jardiance | $89 | 4 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $68 | 3 payments
|
| Alexion Pharmaceuticals | Strensiq | $62 | 2 payments
|
| Dexcom | Dexcom G6 Transmitter | $45 | 1 payment
|
| Abbott Laboratories | Freestyle Libre 3 | $45 | 2 payments
|
| Novo Nordisk | Ozempic | $38 | 2 payments
|
| Radius Health | Tymlos | $36 | 2 payments
|
| Abbvie | Synthroid | $35 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $31 | 2 payments
|
| Kyowa Kirin | Crysvita | $28 | 1 payment
|
| Corcept Therapeutics | Korlym | $28 | 1 payment
|
| Sanofi-Aventis U.S. | Tzield | $27 | 1 payment
|
| Mannkind | Afrezza | $20 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Fasenra | $16 | 1 payment
|
2023: $1,176
| Novo Nordisk | Rybelsus | $224 | 13 payments
|
| Medtronic | Minimed 780g | $155 | 5 payments
|
| Bayer Healthcare Pharmaceuticals | Kerendia | $150 | 9 payments
|
| MannKind | Afrezza | $109 | 4 payments
|
| Abbott Laboratories | Freestyle Libre 3 | $83 | 4 payments
|
| Lilly USA | Trulicity | $73 | 3 payments
|
| Xeris Pharmaceuticals | Gvoke Hypopen | $45 | 2 payments
|
| IBSA Pharma | Licart | $45 | 2 payments
|
| Corcept Therapeutics | Korlym | $42 | 2 payments
|
| Amgen | Repatha | $41 | 2 payments
|
| Averitas Pharma | Qutenza | $31 | 1 payment
|
| Alexion Pharmaceuticals | Strensiq | $28 | 1 payment
|
| Sanofi-Aventis U.S. | Toujeo | $28 | 1 payment
|
| Ascendis Pharma | None | $26 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $23 | 1 payment
|
| Boehringer Ingelheim Pharmaceuticals | Synjardy | $22 | 1 payment
|
| Novartis Pharmaceuticals | Leqvio | $19 | 1 payment
|
| CeQur | Cequr Simplicity | $18 | 1 payment
|
| Radius Health | None | $15 | 1 payment
|
2022: $866
| AstraZeneca Pharmaceuticals LP | Farxiga | $175 | 6 payments
|
| Corcept Therapeutics | Korlym | $118 | 3 payments
|
| Horizon Therapeutics plc | Tepezza | $81 | 3 payments
|
| Bayer HealthCare Pharmaceuticals | Kerendia | $62 | 3 payments
|
| Novo Nordisk | Ozempic | $56 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $49 | 3 payments
|
| Novartis Pharmaceuticals | Entresto | $44 | 2 payments
|
| Mannkind | Afrezza | $42 | 2 payments
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $42 | 2 payments
|
| Alexion Pharmaceuticals | Strensiq | $33 | 2 payments
|
| Radius Health | Tymlos | $31 | 1 payment
|
| Lilly USA | Trulicity | $28 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Pfs | $22 | 1 payment
|
| Amgen | Repatha | $20 | 1 payment
|
| GRT US Holding | Qutenza | $19 | 1 payment
|
| Insulet | Omnipod | $19 | 1 payment
|
| Dexcom | Dexcom G6 Transmitter | $14 | 1 payment
|
| Medtronic | Inpen Smart Insulin Delivery System | $12 | 1 payment
|
2021: $473
| GlaxoSmithKline | Trelegy Ellipta | $113 | 5 payments
|
| Medtronic | Minimed 770g System | $73 | 1 payment
|
| Lilly USA | Baqsimi | $64 | 3 payments
|
| Novo Nordisk | Ozempic | $58 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Breztri | $47 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $33 | 2 payments
|
| Alexion Pharmaceuticals | Strensiq | $27 | 1 payment
|
| Sanofi-Aventis U.S. | Soliqua 100/33 | $22 | 1 payment
|
| Xeris Pharmaceuticals | Gvoke Pfs | $22 | 1 payment
|
| Insulet | Omnipod | $13 | 1 payment
|
2020: $501
| Amgen | Prolia | $252 | 3 payments
|
| iRhythm Technologies | Zio Patch | $66 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $51 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $43 | 3 payments
|
| Antares Pharma | Otrexup | $31 | 1 payment
|
| IBSA Pharma | Tirosint | $24 | 1 payment
|
| Merck Sharp & Dohme | Januvia | $18 | 1 payment
|
| Lilly USA | Trulicity | $15 | 1 payment
|
2019: $504
| Sanofi-Aventis U.S. | Toujeo | $175 | 5 payments
|
| Novo Nordisk | Ozempic | $122 | 10 payments
|
| Mannkind | Afrezza | $64 | 3 payments
|
| Octapharma USA | Cutaquig | $38 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $32 | 2 payments
|
| Amgen | Repatha | $17 | 1 payment
|
| Companion Medical | Inpen | $16 | 2 payments
|
| GlaxoSmithKline | Breo | $15 | 1 payment
|
| Ferring Pharmaceuticals | Zomacton | $13 | 1 payment
|
| Merck Sharp & Dohme | Januvia | $13 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Novo Nordisk AS · Ozempic · 2022 | Their institution | $9,820 |
| Novo Nordisk AS · Ozempic · 2020 | Their institution | $8,950 |
| Novo Nordisk AS · Ozempic · 2021 | Their institution | $7,660 |
| Novo Nordisk AS · Ozempic · 2019 | Their institution | $7,605 |
Professional record
- NPI
- 1588839500
- Licence
- CA A110293California A110293: Current · expires 2027-08-31
- Trained
- Icahn School of Medicine at Mount Sinai, 2008 · 18 years ago
- Group
- Jiva Health Inc
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- Yes
- Taxonomy
- Internal medicine (207R00000X); Federal specialty code 207RE0101X (207RE0101X)
- Mailing address
- 2182 East St, Concord, CA, 94520
- NPI first listed
- 2008-04-30
- NPI last updated
- 2016-08-31
This is when the NPI record was last certified, not a medical board exam.